Novel screening approach for developing new stable biotherapeutic formulations

越来越多的用于对抗感染和疾病的药物是以蛋白质为基础的“生物疗法”。这些重要生物疗法的供应仅限于有足够冷链的地区，即冰箱/冷藏室。Arecor是一家生物治疗配方公司，它开发了稳定液体配方以延长货架期的技术。与曼彻斯特大学生物制药卓越中心合作，Arecor将利用TSB制定的产品赠款，从室温稳定的快速胰岛素新配方开始，资助新一代室温稳定的液体生物治疗配方的开发。这些新的生物治疗制剂可以运往世界任何地方，而不需要冷链储存。联合利华、礼来公司和PrismTC都将协助开发这项新技术，该技术将改善对第三世界的医疗保健供应，并减少冷链供应的环境负担。

A growing number of drugs that are being developed to combat infection and disease are protein based "biotherapeutics". The supply of these vital biotherapeutics is limited only to areas where there is a sufficient cold-chain i.e. fridges/freezers. Arecor is a biotherapeutic formulation company that has developed technology to stabilise liquid formulations to improve their shelf life. In collaboration with Manchester University's Centre of Excellence in Biopharmaceuticals, Arecor will use the TSB formulated product grant to fund the development of the next generation liquid biotherapeutic formulations that are room temperature stable starting with a new room temperature stable formulation of fast acting insulin. These new biotherapeutic formulations can be shipped to any part of the world without the need for cold-chain storage. Unilever, Lilly and PrismTC will all assist in the development of this new technology that will improve healthcare provision to the third world and reduce the environmental burden of cold-chain provision.